Trial Profile

A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Aug 2025 Planned End Date changed from 1 Jul 2025 to 1 Dec 2025.
22 Apr 2025 Planned End Date changed from 1 Jun 2025 to 1 Jul 2025.
01 Mar 2025 Results evaluating safety and efficacy of tebentafusp (IMCgp100) compared with Investigator's Choice (dacarbazine, ipilimumab or pembrolizumab) published in the Journal of Investigative Dermatology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com